CellSource Co

CellSource Co Equity

The The Equity of CellSource Co (4880.T) as of Oct 27, 2026 is 6.02 B JPY. In the previous year, The Equity was 6.04 B JPY — a change of -0.34% (lower).

Equity

6.02 BJPY

YoY

-0.34%

Last updated:

In 2025, CellSource Co's equity was 6.02 B JPY, a -0.34% increase from the 6.04 B JPY equity in the previous year.

The CellSource Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
401.25 M JPY
Jan 1, 2019
1.61 B JPY
Jan 1, 2020
2.04 B JPY
Jan 1, 2021
2.72 B JPY
Jan 1, 2022
3.79 B JPY
Jan 1, 2023
6.20 B JPY
Jan 1, 2024
6.04 B JPY
Jan 1, 2025
6.02 B JPY
The CellSource Co Equity history
YEAREquityYoY
6.02 BJPY-0.34%
6.04 BJPY-2.66%
6.20 BJPY+63.83%
3.79 BJPY+39.16%
2.72 BJPY+33.19%
2.04 BJPY+27.05%
1.61 BJPY+300.67%
401.25 MJPY+93.05%
207.85 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing CellSource Co's Equity

CellSource Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding CellSource Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating CellSource Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

CellSource Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in CellSource Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about CellSource Co stock

The Equity of CellSource Co is 6.02 B JPY in 2025.

The Equity of CellSource Co changed from 6.04 B JPY to 6.02 B JPY, representing a -0.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity CellSource Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CellSource Co

All Key Metrics — CellSource Co